Bharat Biotech in tie-up with the US-based company FluGen and University of Wisconsin Madison to develop a vaccine named “Coro-Flu” to fight against COVID-19. CoroFlu will build on the backbone of FluGen’s flu vaccine candidate known as M2SR.
Click Here To Get Test Series For SBI PO 2020
The vaccine is being developed on the basis of FluGen’s flu vaccine candidate known as M2SR, a self-limited version of the influenza virus. It induces an immune response against the flu. The vaccine will be built by FluGen’s lab that inserts gene sequences from SARS-CoV-2, the novel coronavirus that causes the disease COVID-19 into M2SR so that the novel vaccine will also induce immunity against the coronavirus.
Important takeaways for all competitive exams:
- Headquarters of Bharat Biotech: Hyderabad,Telangana.
- Chairman and Managing Director of Bharat Biotech: Krishna M Ella.
Find More News Related to Agreements